13 / 74 · 1:05 · Original AXON film
Noopept
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
NOOPEPT | Peptide-like compound
Noopept is a synthetic peptide-like compound studied in brain research. It is often discussed alongside its structural relationship to cycloprolylglycine. [1]
RAT STUDY | NGF and BDNF expression
In rats, researchers reported changes in the expression of nerve growth factor and brain-derived neurotrophic factor in the hippocampus. These are molecular findings, not a memory guarantee. [2]
Patient studies ≠ healthy enhancement
Human comparative reports involved people with cognitive problems related to vascular disease or injury. They cannot establish sharper thinking in healthy users or prevention of dementia. [3]
No enhancement or prevention claim
FDA has taken action against unapproved Noopept drug claims. Keep the discussion grounded in the study population and measured endpoint, rather than promises of focus or brain repair. [4]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) →Primary analytical chemistry; structural relationship to cycloprolylglycine
- Noopept stimulates the expression of NGF and BDNF in rat hippocampus →Primary rat molecular study
- Comparative studies of Noopept and piracetam in patients with mild cognitive disorders of vascular and traumatic origin →Primary comparative human clinical report, not a healthy-adult enhancement trial
- FDA warning letter: Peak Nootropics LLC / Advanced Nootropics →US regulator; unapproved-drug enforcement, 2019
